Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
NCT04292769
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Malignant Neoplasm
Interventions
DRUG:
Decitabine
BIOLOGICAL:
DC-CIK
Sponsor
Li Yu